Start-Ups Look For Places In Future HCV Combo Regimens
This article was originally published in Start Up
Executive Summary
With more than 50 drugs in development for hepatitis C, what comes next after first-generation protease inhibitors and what opportunity might there be for small start-up firms in a space where so many Big Pharma and specialty pharma companies are active? Approvals of direct-acting antiviral therapies are just around the corner in hepatitis C, and smaller companies are looking to provide parts of the puzzle in next-generation drug cocktails that will tackle the growing disease. However, in order for small companies to succeed in this highly competitive space they'll need highly differentiated products. START-UP profiles AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus.
You may also be interested in...
BioCryst Joins HCV Race With $101M Presidio Merger
BioCryst’s proposed merger with Presidio will give the company an instant HCV pipeline. Albeit early-stage, the variety of the drugs could give the company a strong hand against other players in the field.
A Few Companies Bet On Continuing Role For Interferon Therapy In HCV
Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.
A Few Companies Bet On Continuing Role For Interferon Therapy In HCV
Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.